Selitrectinib
- Generic Name
- Selitrectinib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C20H21FN6O
- CAS Number
- 2097002-61-2
- Unique Ingredient Identifier
- 0J45910S3X
- Background
Selitrectinib is under investigation in clinical trial NCT03215511 (Phase 1/2 Study of LOXO-195 in Patients With Previously Treated NTRK Fusion Cancers).
- Associated Conditions
- -
- Associated Therapies
- -
Emerging TRK Inhibitors Are Explored Across Cancer Settings
Gene fusions, particularly NTRK, drive cancer progression and have led to targeted therapies like larotrectinib and entrectinib. These fusions are rare but crucial in specific cancers, with some patients experiencing long-term remissions. Resistance mechanisms and the development of second-generation TRK inhibitors aim to overcome treatment challenges.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath